Still a ways off from being easy to use......
https://goo.gl/8gYrxI
Early this year, the FDA approved the Inspire device for use in patients who are unresponsive to or intolerant of other treatments for OSA. This device operates by generating electrical stimulation, which advances the tongue forward and opens the pharyngeal airway during respiration. It is made up of three implanted elements: a breathing sensor, a small electrical impulse generator and a hypoglossal nerve stimulator. The system is activated by a handheld remote control device for nightly use.
At Cleveland Clinic, implantation is performed on an outpatient basis for those patients who meet the eligibility requirements. Ideal candidates are older than 18 years, have an apnea/hypopnea index (AHI) between 20 and 65 and a body mass index of less than 32, and have previously failed CPAP use. Once an eligible candidate is identified, sedated endoscopy is performed to confirm that the patient’s pattern of airway collapse in amenable to Inspire therapy. Also, the results of a recent sleep study must be available for analysis before implantation can be considered. Finally, a repeat sleep study will be performed one month postoperatively so that the device can be titrated to maximal therapeutic effect.